EMEA-001539-PIP01-13-M05
Table of contents
Key facts
Invented name |
Lokelma
|
Active substance |
sodium zirconium cyclosilicate
|
Therapeutic area |
Endocrinology-Gynaecology-Fertility-Metabolism
|
Decision number |
P/0477/2021
|
PIP number |
EMEA-001539-PIP01-13-M05
|
Pharmaceutical form(s) |
Powder for oral suspension
|
Condition(s) / indication(s) |
Treatment of hyperkalaemia
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
AstraZeneca AB
E-mail: paediatrics@astrazeneca.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|